Anti-Dopamine (IgG + IgA) measures the immune system’s activity against dopamine, a key neurotransmitter involved in: • Mood regulation and motivation • Cognition and executive function • Reward and emotional processing • Motor control and coordination • Nervous system stress response The presence of these antibodies suggests the immune system may be reacting to dopamine or dopamine-related structures. This may reflect neuroimmune activation, neurotransmitter dysregulation, or increased permeability in the blood-brain barrier, allowing the immune system to encounter brain-associated molecules. This test does not diagnose a neurological disease. Instead, it acts as an early immune-based marker of possible dopamine pathway stress or autoimmune-associated neuroinflammation. A mild elevation in Anti-Dopamine (IgG + IgA) suggests subtle immune activity toward dopamine-related pathways. This may indicate: • Early-phase neuroimmune signaling • Mild neurotransmitter stress or imbalance • Lifestyle or inflammatory strain affecting dopamine pathways This result does not diagnose a neurological condition. Supportive steps • Improve sleep, stress, and circadian rhythm • Anti-inflammatory diet and omega-3 intake • Regular exercise to support dopamine production • Support gut health and fiber intake • Maintain stable blood sugar • Ensure adequate protein and key nutrients (B6, folate, iron) Helpful to monitor, especially with mood, motivation, or cognitive symptoms.

Anti-Dopamine Receptor 1 (IgG + IgA) – Neural Zoomer Plus (Vibrant America) What is Anti-Dopamine Receptor 1 (IgG + IgA)? The Anti-Dopamine Receptor 1 (D1R) antibodies test measures IgG and IgA antibodies against dopamine receptor 1 (D1R), a key receptor in the brain involved in cognitive function, movement, and motivation. The presence of these antibodies may indicate immune system activity against dopamine receptors, potentially affecting neurological function. Why is this test important? Dopamine receptor dysfunction has been linked to neuropsychiatric and autoimmune conditions, including: Autoimmune encephalitis – A condition where the immune system attacks brain cells, leading to neurological symptoms. Basal ganglia disorders – Such as Sydenham's chorea, where antibodies may disrupt dopamine signaling, causing movement abnormalities. Neuroinflammation & cognitive impairment – Elevated levels may suggest underlying brain inflammation that could contribute to memory issues, anxiety, or depression. What do IgG and IgA mean in this context? IgG antibodies – Suggest chronic or past exposure to an antigen, indicating a longer-term immune response. IgA antibodies – Primarily found in mucosal tissues, suggesting immune activation at the blood-brain barrier or within the nervous system. Interpreting Results Elevated levels may suggest an autoimmune or inflammatory response targeting dopamine receptors, potentially impacting brain function. Low or undetectable levels are generally considered normal and indicate no significant immune response. Next Steps If levels are elevated, further evaluation by a neurologist or functional medicine practitioner may be beneficial. Additional tests for autoimmune encephalitis, PANS/PANDAS, or neuroinflammation could provide deeper insight into potential causes and treatment strategies.

Anti-Dopamine Receptor 2 (IgG + IgA) – Neural Zoomer Plus (Vibrant America) What Is Anti-Dopamine Receptor 2 (IgG + IgA)? The Anti-Dopamine Receptor 2 (DRD2) antibodies test measures immune reactivity to dopamine receptor 2 (DRD2) in the brain. Dopamine receptors play a crucial role in neurotransmission, regulating movement, cognition, mood, and behavior. The presence of IgG and IgA antibodies against DRD2 may indicate an autoimmune reaction targeting these receptors. Why Is This Marker Important? Dysregulation of dopamine receptor 2 is linked to neurological, psychiatric, and autoimmune conditions. Elevated Anti-DRD2 IgG or IgA levels may suggest: Neuroinflammation and autoimmune encephalopathy Basal ganglia dysfunction, potentially associated with movement disorders Neuropsychiatric symptoms, including OCD, tics, and mood disorders PANDAS/PANS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections) Post-infectious autoimmunity, particularly after bacterial or viral infections Understanding IgG and IgA Results Elevated IgG: Suggests a systemic, chronic immune response against DRD2, potentially linked to long-term neuroinflammation. Elevated IgA: May indicate mucosal immune activation, such as gut-brain axis dysfunction or an ongoing autoimmune response. Conditions Associated with Anti-DRD2 Antibodies Autoimmune encephalitis Basal ganglia-related movement disorders (e.g., Parkinson’s-like symptoms, dystonia) Schizophrenia and other psychiatric disorders Obsessive-compulsive disorder (OCD) Tic disorders and Tourette syndrome PANDAS/PANS (post-infectious neuroimmune conditions) Potential Causes of Elevated Anti-DRD2 Antibodies Molecular mimicry (cross-reactivity from infections like streptococcus or viruses) Dysbiosis and leaky gut (gut-brain axis dysfunction) Chronic neuroinflammation Environmental triggers, including toxins or heavy metals What to Do If Your Anti-DRD2 Antibodies Are Elevated If this marker is elevated, further evaluation may be necessary. Potential next steps include: Functional neurology or immunology evaluation Checking for infections (e.g., Streptococcus, Lyme disease, viral triggers) Assessing gut health (intestinal permeability, microbiome imbalances) Addressing neuroinflammation with anti-inflammatory and neuroprotective strategies Considering autoimmune modulation therapies Final Thoughts The presence of Anti-Dopamine Receptor 2 (IgG + IgA) antibodies on the Neural Zoomer Plus panel may indicate an underlying autoimmune or neuroimmune process. Identifying and addressing potential triggers can be key to managing symptoms and restoring neurological balance. If you have concerns about your results, consult a healthcare professional specializing in neuroimmunology or functional medicine.

The Anti-dsDNA antibody test, particularly the Farr assay, is a highly specific diagnostic tool pivotal in the evaluation and management of systemic lupus erythematosus (SLE), a complex autoimmune disorder. Double-stranded DNA (dsDNA) antibodies are a type of antinuclear antibody (ANA) that specifically target the DNA within the cell nucleus. These antibodies are considered one of the hallmark indicators of SLE, with their presence being a key criterion in the diagnosis of the disease. The Farr assay, a radioimmunoassay, is renowned for its high specificity in detecting anti-dsDNA antibodies. This assay utilizes radiolabeled DNA to capture antibodies from a patient's serum. The bound antibodies are then measured, providing a quantitative assessment of the anti-dsDNA antibodies present. A positive Farr assay is strongly indicative of SLE, as these antibodies are rarely found in healthy individuals or those with other autoimmune disorders. The presence and levels of anti-dsDNA antibodies, as determined by the Farr assay, are not only critical in confirming a diagnosis of SLE but also invaluable in monitoring the disease's activity and severity. Fluctuations in the levels of these antibodies often correlate with disease flare-ups and remissions, making them a useful marker in assessing response to treatment and guiding clinical decision-making. For patients suspected of having SLE, or for those managing the condition, the Anti-dsDNA antibody test via the Farr assay is a crucial component of the diagnostic and monitoring process. It provides clarity in distinguishing SLE from other autoimmune conditions and helps in tailoring individualized treatment plans.

The "Anti-Endothelin A Receptor" marker plays a critical role in the NeuralZoomer panel. Endothelin A receptor is a protein found on the surface of certain cells within the body and is involved in regulating various functions, including blood pressure and inflammation. When the immune system mistakenly targets and produces antibodies against the endothelin A receptor, it can lead to vascular issues and contribute to the development of autoimmune diseases. Endothelin peptides modulate the development of distinct neural cell types, including Schwann cells, astrocytes, and neural crest cells, as well as physiologic growth and development. The endothelin A receptor has a greater affinity for ET-1, one of the peptides of endothelin. The endothelin A receptor auto-antibodies are found in vascular dementia.

What is Anti-Fodrin Ab, IgA (RDL)? Anti-Fodrin Antibody, IgA is a blood test that detects IgA-class autoantibodies targeting fodrin, a protein found inside the cells of the salivary and tear glands. These autoantibodies are part of an immune response that mistakenly attacks the body's own moisture-producing tissues—especially in Sjögren’s syndrome. Unlike IgG antibodies, which are more systemic, IgA antibodies are often involved in mucosal and glandular immune responses. Measuring Anti-Fodrin IgA can provide valuable insight into localized glandular autoimmunity—particularly in the early or seronegative stages of disease. Why is this test important? This test is most commonly ordered to help diagnose: Sjögren’s syndrome, especially in patients with chronic dry mouth, dry eyes, or salivary gland swelling Seronegative cases, where common markers like Anti-SSA (Ro) and Anti-SSB (La) are negative Early autoimmune gland involvement before full-blown disease develops What does a positive Anti-Fodrin IgA result mean? A positive Anti-Fodrin Ab, IgA result may indicate: Immune system activity against salivary or lacrimal glands, supporting a diagnosis of Sjögren’s syndrome Possible early-stage or localized autoimmune disease involving mucosal tissues Glandular involvement in other autoimmune conditions, such as lupus or autoimmune thyroid disease This marker is not exclusive to Sjögren’s but is considered helpful when used in combination with symptoms and other test results. What does a negative result mean? A negative Anti-Fodrin IgA result suggests that your immune system is not currently producing detectable IgA antibodies against fodrin. However, this does not rule out Sjögren’s or other autoimmune diseases—other markers or gland biopsies may still be needed, especially if symptoms persist. What happens next if elevated? If your Anti-Fodrin Ab, IgA level is elevated: Your provider may evaluate other markers (e.g., Anti-SSA, ANA, ESR/CRP) and clinical symptoms You might be referred to a rheumatologist for further diagnosis and care Management may involve symptom control (e.g., artificial tears, saliva stimulants), anti-inflammatory treatment, and monitoring for systemic involvement Bottom Line Anti-Fodrin Ab, IgA (RDL) is a useful autoimmune marker for identifying immune system activity targeting glandular tissues, particularly in suspected Sjögren’s syndrome. It may be especially helpful in early-stage or seronegative cases, providing another diagnostic tool when traditional markers are absent. If you’re experiencing symptoms like dry mouth, dry eyes, or salivary gland swelling, this test can offer important insight.

What is Anti-Fodrin Ab, IgG (RDL)? Anti-Fodrin Antibody, IgG is a blood test that looks for autoantibodies targeting a protein called fodrin, which is part of the structural framework (cytoskeleton) inside certain cells—especially those in salivary and tear glands. When the immune system mistakenly attacks fodrin, it can lead to glandular inflammation and dysfunction, contributing to autoimmune conditions. This marker is often used to help diagnose Sjögren’s syndrome, a chronic autoimmune disorder that causes dry mouth, dry eyes, and sometimes systemic symptoms like joint pain and fatigue. What does a positive result mean? A positive Anti-Fodrin Ab, IgG test indicates the presence of immune activity against glandular tissues. This supports a possible diagnosis of: Sjögren’s syndrome, especially in early or “seronegative” cases Other autoimmune diseases like lupus or rheumatoid arthritis with gland involvement This marker is especially useful when classic Sjögren’s antibodies like Anti-SSA (Ro) or Anti-SSB (La) are negative but symptoms still point toward autoimmune glandular disease. What does a negative result mean? A negative result means no detectable anti-fodrin IgG antibodies were found. This doesn’t completely rule out Sjögren’s or other autoimmune conditions—your doctor will consider your symptoms and may order further tests or imaging. Next steps if elevated If your result is positive: Your provider may refer you to a rheumatologist for further evaluation Additional tests (ANA, SSA/SSB, RF, CRP/ESR) may be ordered Management may include tear and saliva substitutes, immunomodulatory therapy, and regular monitoring for complications Bottom Line Anti-Fodrin Ab, IgG (RDL) is a valuable marker for detecting autoimmune activity affecting the body’s moisture-producing glands. It plays a key role in supporting the diagnosis of Sjögren’s syndrome, especially when other antibodies are negative but symptoms persist. Early detection can lead to better symptom control and monitoring for related autoimmune conditions.